Biouniversa creates a strategic partnership with two important American funds, creating a new company in California.
Biouniversa is focused on discovery and development of Diagnostic and Therapeutic Products based on Founders’ discovery of the biological properties of the BAG3 protein on cell death regulation. BAG3 specific reagents showed several applications in the diagnosis and treatment of human diseases involving a disregulation of cell death, specifically cancers and cardiovascular diseases.
More information: https://www.fiercebiotech.com/biotech/intrepida-bio-uncloacks-9-5m-and-anti-bag3-cancer-programs-from-italy